It turns out, they like us, or so they say. Biomedical researchers should take note that for the second year in a row, U.S. Senate appropriators have declared funding the National Institutes of Health a national priority. In a resource-constrained environment, the Senate Labor-Health and Human Services Appropriations Subcommittee (Labor-HHS) recommended that the NIH be provided a $2 billion increase for FY17, recommending $34 billion for FY17.
“Investments in biomedical research will lower health care costs, spur medical innovation, sustain America’s competitiveness, and help more Americans live longer, healthier lives,” declared Sen. Roy Blunt (R-MO), chair of the Subcommittee, “I’m proud that we are establishing a pattern of responsibly investing in groundbreaking medical research for the second year in a row.”
The measure has broad support from Democrats, making it the first bipartisan Labor-HHS appropriations bill in seven years. Ranking Member Senator Patty Murray (D-WA) acknowledged, “Hard choices had to be made.”
The proposed increase includes an additional $100 million for the new Precision Medicine Initiative million-person cohort program, as well as an additional $400 million for Alzheimer’s disease research. It also includes increases of $100 million for the BRAIN Initiative and $50 million for research to combat antimicrobial resistance.
The bill outlines increased funding for every NIH Institute and Center. The new money is to support investments that advance science and speed the development of new therapies, diagnostics, and preventive measures, all to improve the American health. This is great news for basic scientists. This proposed funding will enable researchers throughout the U.S. to answer new support in fields such as cell biology, biophysics, genetics, developmental biology, and so many other areas.
The House has not yet written its own version of the NIH bill. However, Rep. Tom Cole (R-OK), the chair of the House Labor-HHS Appropriations Subcommittee, has recently gone out of his way to state his public supportive for the NIH and pledged to include a $2 billion increase in the House bill.
“It’s terrific to see bipartisan support for biomedical research, but there’s still a long way to go before this bill gets signed into law,” warns Keith Yamamoto, chair of the CLS. “We will continue to engage Congress on this bill to ensure the best outcome for NIH-funded researchers.”
Meanwhile all eyes turn to the House to see whether biomedical research is the object of true Congressional love or just a passing fiscal fancy.